Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Neuroblastoma and MYCN.

Neuroblastoma and MYCN. Neuroblastoma, the most common extracranial solid tumor of childhood, is thought to originate from undifferentiated neural crest cells. Amplification of the MYC family member, MYCN, is found in ∼25% of cases and correlates with high-risk disease and poor prognosis. Currently, amplification of MYCN remains the best-characterized genetic marker of risk in neuroblastoma. This article reviews roles for MYCN in neuroblastoma and highlights recent identification of other driver mutations. Strategies to target MYCN at the level of protein stability and transcription are also reviewed. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cold Spring Harbor Perspectives in Medicine Pubmed

Neuroblastoma and MYCN.

Cold Spring Harbor Perspectives in Medicine , Volume 3 (10): -14414999999 – May 27, 2014

Neuroblastoma and MYCN.


Abstract

Neuroblastoma, the most common extracranial solid tumor of childhood, is thought to originate from undifferentiated neural crest cells. Amplification of the MYC family member, MYCN, is found in ∼25% of cases and correlates with high-risk disease and poor prognosis. Currently, amplification of MYCN remains the best-characterized genetic marker of risk in neuroblastoma. This article reviews roles for MYCN in neuroblastoma and highlights recent identification of other driver mutations. Strategies to target MYCN at the level of protein stability and transcription are also reviewed.

Loading next page...
 
/lp/pubmed/neuroblastoma-and-mycn-MmPw0w5GjZ

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
2157-1422
eISSN
2157-1422
DOI
10.1101/cshperspect.a014415
pmid
24086065
Publisher site
See Article on Publisher Site

Abstract

Neuroblastoma, the most common extracranial solid tumor of childhood, is thought to originate from undifferentiated neural crest cells. Amplification of the MYC family member, MYCN, is found in ∼25% of cases and correlates with high-risk disease and poor prognosis. Currently, amplification of MYCN remains the best-characterized genetic marker of risk in neuroblastoma. This article reviews roles for MYCN in neuroblastoma and highlights recent identification of other driver mutations. Strategies to target MYCN at the level of protein stability and transcription are also reviewed.

Journal

Cold Spring Harbor Perspectives in MedicinePubmed

Published: May 27, 2014

There are no references for this article.